5 posts on this topic, sorted most recent first.
The peptide market splits into licensed pharmaceutical, licensed compounded, and research-chemical-flavored compounded. The middle category has wide quality variance. Here's how to actually tell them apart.
I keep getting the same question from different friends in different cities. Here's the version short enough to get through over coffee. The decision today (May 2026) is different from the one a year ago, and the difference is mostly about what you actually want from your supply chain.
A friend asked me last week whether to keep paying $179 a month for compounded tirzepatide from her telehealth provider. The honest answer involves the April 30 FDA proposal, the difference between 'still shipping' and 'safe to bet on', and a conversation about what brand pricing looks like once she does the math on insurance.
Most clinic intake forms are designed to qualify you for a prescription, not to qualify the clinic for your trust. Here's the inversion: the questions that separate a careful supplier from a cargo-cult one.
The real differences between compounded tirzepatide from a 503A pharmacy and brand Mounjaro from Eli Lilly. Regulatory status, quality control, pricing, and when one is clearly better than the other.